The Patent Finder

Taro Pharmaceutical Industries Ltd.

10 patents currently held · Updated Nov 17, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 6 name spellings.

2
Ending by 2030
Dec 2026
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jan 4, 2027
    The maintenance fee for Preparation of Trifarotene and Intermediates and Polymorphs Thereof (US 11,691,946) comes due Jan 4, 2027. Unpaid by Jul 6, 2027, it lapses early.
  • 1 fee due Jun 19, 2027
    The maintenance fee for Topical Montelukast formulations (US 11,844,861) comes due Jun 19, 2027. Unpaid by Dec 20, 2027, it lapses early.
  • 1 fee due Aug 4, 2027
    The maintenance fee for Topical montelukast for treatment of atopic dermatitis (US 10,548,837) comes due Aug 4, 2027. Unpaid by Feb 4, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 term has ended since Aug 19, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 10 of 10

PatentTitleStatus Expires Confidence
US 8,039,657Process for preparing malathion for pharmaceutical use
In force
 · From the USPTO record
In forceFrom the USPTO record
US 7,560,445Process for preparing malathion for pharmaceutical use
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,112,970Process for the preparation of 17-desoxy-corticosteroids
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,548,837Topical montelukast for treatment of atopic dermatitis
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,612,607Fenoldopam Topical Formulations for Treating Skin Disorders
In force
 · High confidence
In forceHigh confidence
US 11,559,541Topical Capecitabine for the Treatment of Hyperproliferative Skin Conditions
In force
 · High confidence
In forceHigh confidence
US 11,691,946Preparation of Trifarotene and Intermediates and Polymorphs Thereof
In force
 · High confidence
In forceHigh confidence
US 11,173,117Topical Montelukast formulations
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,844,861Topical Montelukast formulations
In force
 · From the USPTO record
In forceFrom the USPTO record
US 12,233,055Topical Montelukast formulations
In force
 · From the USPTO record
In forceFrom the USPTO record
Also on record, not counted in the 10: 29 lapsed for an unpaid fee · 19 ended at full term · 1 surrendered on reissue. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

2 pending · 2 abandoned · 16 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited